SFO issues injection guidelines
Maintain fixed intervals and opt for same-day bilateral injections


Dermot McGrath
Published: Friday, March 20, 2020
The French Society of Ophthalmology (SFO), through its president Prof Laurent Kodjikian, has issued specific guidelines to its members concerning the administration of intravitreal injections (IVI) in light of the COVID-19 epidemic.
SFO recommends:
In cases of neovascular AMD: maintain injections only, spacing patients over the course of the day and cancelling consultations (therefore no OCT controls) in order to avoid grouping of patients. For this, SFO advises keeping a fixed interval for injections (the minimal necessary to maintain efficacy) and to favour same-day bilateral injections where possible so the patient does not have to return twice to the clinic.
Bear in mind that there are specific individual cases that will require the completion of an OCT scan for correct decision-making, in particular for the control of the second eye.
In the case of new vessels linked to high myopia or inflammatory pathologies:
The same strategy as above for nAMD can be applied for these patients.
In case of diabetic macular oedema (DME) and macular oedema after retinal vein occlusion:
A postponement does not generally jeopardise the functional prognosis and can be performed at a later stage in the vast majority of cases.
Angiograms deemed necessary for decision-making and urgent laser treatments (such as pan-retinal photocoagulation for severe proliferative diabetic retinopathy) can be maintained, but only sparingly. The monitoring and treatment of proliferative and severe diabetic retinopathy should not be interrupted.
Finally, SFO said it was vital to continue to treat ocular emergencies by all centres with the capability to do in terms of respecting the requisite sanitary controls for COVID-19 and to limit as much as possible non-emergency surgical and medical activity for all the population.
Tags: coronavirus, covid-19, covid19
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.